The effect of increased lipoprotein levels on the pharmacokinetics of ketoconazole enantiomers in the rat

References

• Aliabadi HM, Spencer TJ, Mahdipoor P, Lavasanifar A, Brocks DR. (2006). Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function. AAPS J 8:E672–E681.
   PubMed Web of Science ®Google Scholar
• Arakaki R, Welles B. (2010). Ketoconazole enantiomer for the treatment of diabetes mellitus. Expert Opin Investig Drugs 19:185–194.
   PubMed Web of Science ®Google Scholar
• Austin MA. (1999). Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 83:13F–16F.
   PubMed Web of Science ®Google Scholar
• Bailer AJ. (1988). Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16:303–309.
   PubMedGoogle Scholar
• Brocks DR, Ala S, Aliabadi HM. (2006). The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm Drug Dispos 27:7–16.
   PubMed Web of Science ®Google Scholar
• Daneshmend TK, Warnock DW. (1988). Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 14:13–34.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Dilmaghanian S, Gerber JG, Filler SG, Sanchez A, Gal J. (2004). Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality 16:79–85.
   PubMed Web of Science ®Google Scholar
• Eliot LA, Jamali F. (1999). Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. J Pharmacol Exp Ther 291:188–193.
   PubMed Web of Science ®Google Scholar
• Elsherbiny ME, El-Kadi AO, Brocks DR. (2008). The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci 11:147–159.
   PubMed Web of Science ®Google Scholar
• Fan Y, Rodriguez-Proteau R. (2008). Ketoconazole and the modulation of multidrug resistance-mediated transport in Caco-2 and MDCKII-MDR1 drug transport models. Xenobiotica 38:107–129.
   PubMed Web of Science ®Google Scholar
• Fujinami K, Kojima K, Aragane K, Kusunoki J. (2001). Postprandial hyperlipidemia in Zucker diabetic fatty fa/fa rats, an animal model of type II diabetes, and its amelioration by acyl-CoA:cholesterol acyltransferase inhibition. Jpn J Pharmacol 86:127–129.
   Google Scholar
• Genest J, Frohlich J, Fodor G, McPherson R. Working Group on Hypercholesterolemia and Other Dyslipidemias. (2003). Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 169:921–924.
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Shtainer D, Hoffman A. (2007). The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. Int J Pharm 333:1–4.
   PubMedGoogle Scholar
• Hamdy DA, Brocks DR. (2008). A stereospecific high-performance liquid chromatographic assay for the determination of ketoconazole enantiomers in rat plasma. Biomed Chromatogr 22:542–547.
   Google Scholar
• Hamdy DA, Brocks DR. (2009a). Experimental hyperlipidemia causes an increase in the electrocardiographic changes associated with amiodarone. J Cardiovasc Pharmacol 53:1–8.
   PubMed Web of Science ®Google Scholar
• Hamdy DA, Brocks DR. (2009b). Nonlinear stereoselective pharmacokinetics of ketoconazole in rat after administration of racemate. Chirality 21:704–712.
   PubMed Web of Science ®Google Scholar
• Janssen. 1995. Product monograph: Nizoral®, Ketoconazole (Titusville, NJ: Janssen.Pharmaceuticals).
   Google Scholar
• Johnston TP, Palmer WK. (1993). Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 46:1037–1042.
   PubMed Web of Science ®Google Scholar
• Kim HR, Gil S, Andrieux K, Nicolas V, Appel M, Chacun H, Desmaële D, Taran F, Georgin D, Couvreur P. (2007). Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 64:356–364.
   PubMed Web of Science ®Google Scholar
• Korashy HM, Shayeganpour A, Brocks DR, El-Kadi AO. (2007). Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines. Toxicol Sci 97:32–43.
   PubMed Web of Science ®Google Scholar
• Lake-Bakaar G, Scheuer PJ, Sherlock S. (1987). Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 294:419–422.
   PubMed Web of Science ®Google Scholar
• Liu XM, Wu FH. (2004). [Comparison of animal models of hyperlipidemia]. Zhong Xi Yi Jie He Xue Bao 2:132–134.
   PubMedGoogle Scholar
• Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. (1992). Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 2:161–176.
   PubMedGoogle Scholar
• Mashimo T, Ogawa H, Cui ZH, Harada Y, Kawakami K, Masuda J, Yamori Y, Nabika T. (2007). Comprehensive QTL analysis of serum cholesterol levels before and after a high-cholesterol diet in SHRSP. Physiol Genomics 30:95–101.
   Google Scholar
• Matthew D, Brennan B, Zomorodi K, Houston JB. (1993). Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. Pharm Res 10:418–422.
   Google Scholar
• Palmer WK, Emeson EE, Johnston TP. (1997). The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med Sci Sports Exerc 29:1416–1421.
   PubMed Web of Science ®Google Scholar
• Patel JP, Brocks DR. (2009). The effect of oral lipids and circulating lipoproteins on the metabolism of drugs. Expert Opin Drug Metab Toxicol 5:1385–1398.
   PubMed Web of Science ®Google Scholar
• Patel JP, Fleischer JG, Wasan KM, Brocks DR. (2009). The effect of experimental hyperlipidemia on the stereoselective tissue distribution, lipoprotein association and microsomal metabolism of (+/-)-halofantrine. J Pharm Sci 98:2516–2528.
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Barrie E, de Bono JS. (2008). CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 5:610–620.
   PubMedGoogle Scholar
• Riley CM, James MO. (1986). Determination of ketoconazole in the plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography. J Chromatogr 377:287–294.
   PubMed Web of Science ®Google Scholar
• Rotstein DM, Kertesz DJ, Walker KA, Swinney DC. (1992). Stereoisomers of ketoconazole: preparation and biological activity. J Med Chem 35:2818–2825.
   PubMed Web of Science ®Google Scholar
• Rudel LL, Parks JS, Johnson FL, Babiak J. (1986). Low density lipoproteins in atherosclerosis. J Lipid Res 27:465–474.
   Google Scholar
• Russell JC. (2009). Evaluating micro- and macro-vascular disease, the end stage of atherosclerosis, in rat models. Methods Mol Biol 573:17–44.
   Google Scholar
• Schuster I. (1985). The interaction of representative members from two classes of antimycotics–the azoles and the allylamines–with cytochromes P-450 in steroidogenic tissues and liver. Xenobiotica 15:529–546.
   PubMed Web of Science ®Google Scholar
• Shayeganpour A, Jun AS, Brocks DR. (2005). Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 26:249–257.
   PubMed Web of Science ®Google Scholar
• Shayeganpour A, Korashy H, Patel JP, El-Kadi AO, Brocks DR. (2008). The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int J Pharm 361:78–86.
   PubMed Web of Science ®Google Scholar
• Shayeganpour A, Lee SD, Wasan KM, Brocks DR. (2007). The influence of hyperlipoproteinemia on in vitro distribution of amiodarone and desethylamiodarone in human and rat plasma. Pharm Res 24:672–678.
   Google Scholar
• Shiomi M, Ito T. (2009). The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe. Atherosclerosis 207:1–7.
   PubMed Web of Science ®Google Scholar
• Srivastava LS, Kashyap M, Perisutti G, Chen CY. (1977). Induction of hyperlipidemia by human thyroid stimulating hormone immunization in rabbits. Experientia 33:593–595.
   Google Scholar
• Vanden Bossche H, Koymans L, Moereels H. (1995). P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 67:79–100.
   PubMed Web of Science ®Google Scholar
• Wasan KM, Looije NA. (2005). Emerging pharmacological approaches to the treatment of obesity. J Pharm Pharm Sci 8:259–271.
   PubMed Web of Science ®Google Scholar
• Wout ZG, Pec EA, Maggiore JA, Williams RH, Palicharla P, Johnston TP. (1992). Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenter Sci Technol 46:192–200.
   PubMedGoogle Scholar